Ticker:
MYGN

Primary Sector:
Healthcare

Current Stock Price:
$34.32

High/Base/Low Price Projection:
$49/$23/$8

Morgan Stanley's take: "Myriad is now transitioning to a more comprehensive 25 gene panel, myRisk, which tests for hereditary risk of various cancers. Discussions with insurance payors suggest myRisk is meeting resistance for coverage as payors worry about the lack of data proving clinical utility for broad genomic testing and costs."

Ticker:
PH

Primary Sector:
Discretionary/Industrials

Current Stock Price:
$113.21

High/Base/Low Price Projection:
$170/$125/$69

Morgan Stanley's take: "Parker is the purest play on global IP growth to be found in the Machinery group, but uncertainty in the ROW outlook makes material acceleration less likely."

GOLDMAN: Here are the 9 most overpriced stocks in the market »